Get the Stockscreener App
23.19
3.21%
-0.77
After Hours:
23.66
0.47
+2.03%
Catalyst Pharmaceuticals Inc stock is traded at $23.19, with a volume of 926.03K.
It is down -3.21% in the last 24 hours and up +10.06% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
See More
Previous Close:
$23.96
Open:
$24.16
24h Volume:
926.03K
Relative Volume:
0.90
Market Cap:
$2.82B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
19.65
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+3.02%
1M Performance:
+10.06%
6M Performance:
+35.06%
1Y Performance:
+57.01%
1-Day Range:
$23.16
$24.64
1-Week Range:
$22.07
$24.64
52-Week Range:
$13.12
$24.64
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
23.19 | 2.82B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 5.4%Time to Buy? - MarketBeat
Catalyst Pharmaceuticals stock hits all-time high of $24.44 - Investing.com
Is Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Simply Wall St
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Moody Aldrich Partners LLC Cuts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Nilsine Partners LLC Purchases New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Pacer Advisors Inc. - MarketBeat
11,320 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Dakota Wealth Management - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.86 Consensus Target Price from Brokerages - MarketBeat
Charles B. O?Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, Inc - Marketscreener.com
Catalyst Pharmaceuticals board member to retire By Investing.com - Investing.com Canada
(CPRX) Investment Analysis - Stock Traders Daily
Catalyst Pharmaceuticals board member to retire - MSN
Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis - MarketBeat
Catalyst Pharma Announces Board Member’s Departure - TipRanks
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals Receives Prestigious Ranking on - GlobeNewswire
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
FIRDAPSE now available in Japan for muscle weakness - MSN
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - The Manila Times
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Up 12.5% in December - MarketBeat
Redhawk Wealth Advisors Inc. Takes $1.27 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
JPMorgan Chase & Co. Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to "Buy" at StockNews.com - MarketBeat
HC Wainwright Issues Positive Forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price - MarketBeat
Catalyst Settles Patent Fight Against Teva Over Firdapse - Law360
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva - MSN
Catalyst Pharmaceuticals' (CPRX) "Buy" Rating Reiterated at Bank of America - MarketBeat
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical - Yahoo Finance
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - MSN
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 13% HigherWhat's Next? - MarketBeat
Catalyst stock climbs 15% on Firdapse litigation settlement - MSN
Catalyst Pharma Gains, Teva Patent Settlement Seen Positive (1) - Bloomberg Law
Catalyst Pharmaceuticals Reaches Settlement With Teva in Firdapse Patent Litigation - Marketscreener.com
Catalyst Pharmaceuticals Reaches Settlement Deal With Teva Over Firdapse Patent Litigation - Marketscreener.com
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva - MarketWatch
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals - The Manila Times
Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva - TipRanks
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® - GlobeNewswire
Catalyst Pharmaceuticals' (NASDAQ:CPRX) earnings growth rate lags the 37% CAGR delivered to shareholders - Simply Wall St
Oliver Luxxe Assets LLC Purchases 35,225 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Interesting CPRX Call Options For January 17th - Nasdaq
Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to "Strong-Buy" Rating - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
(CPRX) Long Term Investment Analysis - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.46%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):